Page 22 - Express Scripts News Today

CVS Health Corp. plans to change how its more than 9,000 pharmacies get paid with a new reimbursement model designed to simplify drug pricing.

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Zepbound™ (tirzepatide) injection is now available. Zepbound is indicated for adults...

CVS Health, facing the potential for deeper industry consolidation, lifted its 2024 sales forecast and boosted its quarterly dividend.

Eli Lilly & Co. said Tuesday its new obesity drug Zepbound has been added to a major pharmacy benefit manager’s preferred formulary, or list of covered...

SANTA FE, N.M. (Legal Newsline) — Express Scripts faces a lawsuit from the entity handling insurance for public school employees in New Mexico.

/PRNewswire/ -- Today, Prime Therapeutics LLC/Magellan Rx Management LLC (Prime/MRx) announces that it has appointed Ken Bodmer as chief financial officer...

The biggest U.S. drugstore chain aims to make the payment system more transparent by using a formula based on a drug's cost, a fixed markup, and a fee that reflects the value of the pharmacy services, the company said Tuesday.

The industry is moving away from a traditional, complex pricing model and toward the “cost-plus” approach introduced by billionaire Mark Cuban at his pharmacy company.

(Reuters) -Eli Lilly on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not cover the drug, or half the list price. Wall Street analysts expect sales of Zepbound to reach about $2 billion in 2024, and for sales of Novo Nordisk's rival obesity drug Wegovy to hit around $7.5 billion. Pfizer last week said it would not advance its highly-anticipated oral obesity drug danugl...

Policymakers: “Middlemen” between drugmakers and retailers pocket profits to detriment of consumers.